185 related articles for article (PubMed ID: 29724031)
1. Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia.
Wong RWJ; Ishida T; Sanda T
Molecules; 2018 May; 23(5):. PubMed ID: 29724031
[TBL] [Abstract][Full Text] [Related]
2. [Understanding of molecular pathogenesis of T-cell leukemia by super-enhancer profiling].
Sanda T
Rinsho Ketsueki; 2018; 59(7):899-908. PubMed ID: 30078801
[TBL] [Abstract][Full Text] [Related]
3. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
Wong RWJ; Ngoc PCT; Leong WZ; Yam AWY; Zhang T; Asamitsu K; Iida S; Okamoto T; Ueda R; Gray NS; Ishida T; Sanda T
Blood; 2017 Nov; 130(21):2326-2338. PubMed ID: 28978570
[TBL] [Abstract][Full Text] [Related]
4. Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth.
Sakamoto H; Ando K; Imaizumi Y; Mishima H; Kinoshita A; Kobayashi Y; Kitanosono H; Kato T; Sawayama Y; Sato S; Hata T; Nakashima M; Yoshiura KI; Miyazaki Y
Cancer Sci; 2022 Dec; 113(12):4092-4103. PubMed ID: 36047964
[TBL] [Abstract][Full Text] [Related]
5. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
[TBL] [Abstract][Full Text] [Related]
6. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
7. Super enhancers - new analyses and perspectives on the low hanging fruit.
Hamdan FH; Johnsen SA
Transcription; 2018; 9(2):123-130. PubMed ID: 28980882
[TBL] [Abstract][Full Text] [Related]
8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
9. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.
Tasdemir N; Banito A; Roe JS; Alonso-Curbelo D; Camiolo M; Tschaharganeh DF; Huang CH; Aksoy O; Bolden JE; Chen CC; Fennell M; Thapar V; Chicas A; Vakoc CR; Lowe SW
Cancer Discov; 2016 Jun; 6(6):612-29. PubMed ID: 27099234
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
Bacabac M; Xu W
Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
[TBL] [Abstract][Full Text] [Related]
11. Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
Nagel S; Scherr M; Kel A; Hornischer K; Crawford GE; Kaufmann M; Meyer C; Drexler HG; MacLeod RA
Cancer Res; 2007 Feb; 67(4):1461-71. PubMed ID: 17308084
[TBL] [Abstract][Full Text] [Related]
12. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells.
Moles R; Bai XT; Chaib-Mezrag H; Nicot C
J Hematol Oncol; 2016 Nov; 9(1):121. PubMed ID: 27829440
[TBL] [Abstract][Full Text] [Related]
13. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
14. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
15. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.
Kim TK; Lee JS; Oh SY; Jin X; Choi YJ; Lee TH; Lee Eh; Choi YK; You S; Chung YG; Lee JB; DePinho RA; Chin L; Kim H
Cancer Res; 2007 Dec; 67(23):11133-40. PubMed ID: 18056437
[TBL] [Abstract][Full Text] [Related]
16. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
17. BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer.
Liu B; Liu X; Han L; Chen X; Wu X; Wu J; Yan D; Wang Y; Liu S; Shan L; Zhang Y; Shang Y
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35105803
[TBL] [Abstract][Full Text] [Related]
18. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines.
Nagel S; Meyer C; Quentmeier H; Kaufmann M; Drexler HG; MacLeod RA
Leukemia; 2008 Mar; 22(3):600-7. PubMed ID: 18079734
[TBL] [Abstract][Full Text] [Related]
19. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
20. Touch and go: nuclear proteolysis in the regulation of metabolic genes and cancer.
Maneix L; Catic A
FEBS Lett; 2016 Apr; 590(7):908-23. PubMed ID: 26832397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]